Testing an experimental oral tablet for moderate to severe psoriasis
Part of Skin clinical trials.
This early-phase study tests an experimental oral tablet (UA026) in people with moderate to severe plaque psoriasis. The purpose is to see how safe and effective the drug is, and how it works in the body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 70 years old.
- You should have moderate to severe plaque psoriasis that has been stable for at least 6 months and covers at least 10% of your body.
- You cannot have used certain psoriasis treatments (like some biologics or phototherapy) within the past few weeks or months, depending on the treatment.
- You should not have had a serious infection, TB, or certain other health conditions (like liver problems, heart failure, or a history of cancer).
- For women of childbearing age and men who can father children, you must use birth control and not donate eggs or sperm during and for a while after the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a new oral medication called D-2570 can safely and effectively treat moderate to severe plaque psoriasis. It may be an option if your psoriasis covers a large area and has been stable for at least 6 months.
This study tests an experimental oral medication (a TYK2 inhibitor) for people with moderate to severe plaque psoriasis. It aims to see if the drug is safe and effective at reducing psoriasis symptoms.
This trial tests an experimental pill called D-2570 for people with moderate to severe plaque psoriasis. It aims to see if the pill can safely improve skin symptoms like redness, scaling, and thickness.
This trial tests a new oral medication, CS32582, for people with moderate to severe plaque psoriasis. It aims to see if the drug is safe and effective at reducing skin symptoms like redness, thickness, and scaling.
This trial tests a new study drug (ZP9830) to see if it is safe and works well for people with plaque psoriasis. You would receive the treatment for 8 weeks, and the study will check how your skin responds.
This study tests an oral medication (HSK47388) as a treatment for moderate-to-severe plaque psoriasis, the most common type. It may help reduce symptoms like red, scaly patches and improve quality of life.
Hear when a new Plaque Psoriasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.